More reports from the UK on the use of BTM in non-burn wound reconstruction.
Two abstracts from the University Hospitals Coventry & Warwickshire have been published in the Annals of the Royal College of Surgeons of England, March 2024.
Both abstracts report on a retrospective observational study of 37 patients who underwent non-burn wound reconstruction using Novosorb BTM between January 2020 and September 2022.
Conclusions This study underscores Novosorb as a valuable addition to non-burn wound management, even in challenging clinical scenarios. Vigilant clinical monitoring and meticulous wound bed optimisation are essential, especially for elderly, diabetic, or co-morbid patients with chronic or malignant wounds. Despite potential complications, Novosorb consistently proves to be a robust and reliable choice for enhancing patient outcomes in non-burn wound reconstruction.
- Wound aetiologies included: acute trauma (51.4%), chronic wounds (24.3%), infections with tissue loss (16.2%), and soft tissue or skin cancer (8.1%).TBSA was 1%, most frequent wound site was lower limb (56.8%), whereas wound bed was muscle/fascia (48.6%).
- There was a 74.3% success rate in achieving Novosorb integration.
- Notably, all patients achieved complete wound healing. Median time to complete wound healing was 101 days.
- Patients aged 65 and above experienced higher complication rates (72.7%), while younger patients exhibited significantly lower complication rates (34.6%).
- Complications occurred in 45.9% of patients: highest rates seen in cases involving malignancy (66.7%) and chronic wounds (55.6%).
- Factors such as wound bed characteristics, and diabetic status showed no substantial influence on either integration or complication rates.
- Age, gender and smoking history were not significantly associated with BTM loss.
- Forums
- ASX - By Stock
- PNV
- The Clinicians Speak
The Clinicians Speak, page-844
-
- There are more pages in this discussion • 190 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.66 |
Change
0.080(3.10%) |
Mkt cap ! $1.836B |
Open | High | Low | Value | Volume |
$2.60 | $2.67 | $2.56 | $2.493M | 951.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 13090 | $2.65 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.66 | 11236 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
32 | 18246 | 2.650 |
15 | 26533 | 2.640 |
17 | 73617 | 2.630 |
13 | 61728 | 2.620 |
16 | 186477 | 2.610 |
Price($) | Vol. | No. |
---|---|---|
2.660 | 11683 | 17 |
2.670 | 40193 | 19 |
2.680 | 60891 | 19 |
2.690 | 76944 | 13 |
2.700 | 217163 | 16 |
Last trade - 13.45pm 31/07/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online